Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J Clin Oncol 2018; 9(8): 172-179 [PMID: 30622925 DOI: 10.5306/wjco.v9.i8.172]
Corresponding Author of This Article
Bruna Scaggiante, PhD, Professor, Department of Life Sciences, University of Trieste, Via Giorgeri, 1, Trieste 34127, Italy. bscaggiante@units.it
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Navid Sobhani, Daniele Generali, Fabrizio Zanconati, Marina Bortul, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Academic Hospital, Trieste 34149, Italy
Bruna Scaggiante, Department of Life Sciences, University of Trieste, Trieste 34127, Italy
Author contributions: Sobhani N proposed and planned the topic of the editorial and wrote the first draft that has been revised and implemented by Generali D and Scaggiante B; Zanconati F and Bortul M further edited the manuscript.
Supported byRicerca Sanitaria LILT 2015; and Beneficentia Foundation Stiftung, No. BEN2016/16 grants.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Bruna Scaggiante, PhD, Professor, Department of Life Sciences, University of Trieste, Via Giorgeri, 1, Trieste 34127, Italy. bscaggiante@units.it
Telephone: +39-34-59700000
Received: July 13, 2018 Peer-review started: July 13, 2018 First decision: October 8, 2018 Revised: October 16, 2018 Accepted: November 26, 2018 Article in press: November 26, 2018 Published online: December 20, 2018 Processing time: 161 Days and 11.3 Hours
Core Tip
Core tip: The phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) pathway sustains cancer progression and drug resistance. The first Food and Drug Administration approved molecule against this pathway was everolimus, an mTOR inhibitor, to be used in combination with exemestane in hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancers progressing to non-steroidal aromatase inhibitors. Drugs targeting other effectors such as PI3K, PI3Kα, Akt and mTORC1/2 have gained clinical interest. Nevertheless, everolimus remains the best option due to the relevant toxicity of the other drugs targeting the PI3K-mTOR pathway. Future directions point towards the development of biomarkers that would identify those patients who would benefit from the PI3K-mTOR inhibitors for improving overall survival.
